TrialThe Lancet. Oncology2021

Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial.

Yunpeng Yang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.